Parkman Healthcare Partners LLC Acquires 1,201,943 Shares of Xeris Biopharma Holdings, Inc. $XERS

Parkman Healthcare Partners LLC lifted its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 207.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,780,454 shares of the company’s stock after purchasing an additional 1,201,943 shares during the quarter. Parkman Healthcare Partners LLC’s holdings in Xeris Biopharma were worth $9,775,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in XERS. Millennium Management LLC raised its holdings in Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after acquiring an additional 369,420 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Xeris Biopharma by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after acquiring an additional 3,594 shares in the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Xeris Biopharma in the 1st quarter valued at $1,403,000. Bosun Asset Management LLC acquired a new position in Xeris Biopharma in the 1st quarter valued at $467,000. Finally, AQR Capital Management LLC raised its holdings in Xeris Biopharma by 13.4% in the 1st quarter. AQR Capital Management LLC now owns 946,766 shares of the company’s stock valued at $5,198,000 after acquiring an additional 111,826 shares in the last quarter. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Trading Down 0.5%

Shares of Xeris Biopharma stock opened at $7.85 on Friday. The business has a 50-day moving average price of $6.19 and a two-hundred day moving average price of $5.14. Xeris Biopharma Holdings, Inc. has a 1-year low of $2.49 and a 1-year high of $8.03. The company has a market cap of $1.27 billion, a P/E ratio of -37.38 and a beta of 0.13.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.02. The business had revenue of $67.71 million for the quarter, compared to analyst estimates of $64.58 million. Equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on XERS. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Friday. Leerink Partners upped their price objective on Xeris Biopharma from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 19th. Oppenheimer upped their price objective on Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Friday, May 9th. Finally, HC Wainwright began coverage on Xeris Biopharma in a report on Tuesday, August 12th. They set a “buy” rating and a $10.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.08.

Insider Activity at Xeris Biopharma

In related news, Director Jeffrey W. Sherman sold 42,232 shares of the company’s stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $7.92, for a total value of $334,477.44. Following the sale, the director owned 219,188 shares in the company, valued at $1,735,968.96. This represents a 16.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Kevin Mcculloch bought 25,000 shares of the stock in a transaction that occurred on Friday, June 13th. The stock was acquired at an average price of $4.38 per share, for a total transaction of $109,500.00. Following the acquisition, the insider directly owned 1,708,585 shares in the company, valued at $7,483,602.30. The trade was a 1.48% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 192,232 shares of company stock worth $1,430,777 over the last quarter. Company insiders own 6.47% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.